source
- Epicrispr and Infinimmune secure $165 million in venture funding for epigenetic and antibody programsEpicrispr Biotechnologies announced a $90 million Series C round to push its epigenetic therapy program for facioscapulohumeral muscular dystrophy (FSHD). The lead candidate, EPI-321, is in a firs…
- Hims & Hers says it can quickly launch six wellness peptides if FDA lifts banHims & Hers used its second‑quarter earnings call to explain that it is preparing to offer six consumer wellness peptides that are currently prohibited for compounding pharmacies. The company says…